The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis
Open accessAbstract
Vancomycin and teicoplanin are the glycopeptides currently in use for the treatment of infections caused by invasive beta-lactam-resistant gram-positive organisms. We conducted a systematic review and meta-analysis of randomized controlled trials that have compared vancomycin and teicoplanin administered systemically for the treatment of suspected or proven infections. A comprehensive search of trials without year, language, or publication status restrictions was performed. The primary outcome was all-cause mortality. Two reviewers independently extracted the data. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled by using the fixed-effect model (RRs of >1 favor vancomycin). Twenty-four trials were included. All-cause mortality was similar overall (RR, 0.95; 95% CI, 0.74 to 1.21), and there was no significant heterogeneity. In trials that used adequate allocation concealment, the results favored teicoplanin (RR, 0.82; 95% CI, 0.63 to 1.06), while in trials with unknown methods or inadequate concealment, the results favored vancomycin (RR, 3.61; 95% CI, 1.27 to 10.30). The latter trials might have recruited more severely ill patients. No other variable affected the RRs for mortality, including the assessment of glycopeptides administered empirically or for proven infections, neutropenia, the participant's age, and drug dosing. There were no significant differences between teicoplanin and vancomycin with regard to clinical failure (RR, 0.92; 95% CI, 0.81 to 1.05), microbiological failure (RR, 1.24; 95% CI, 0.93 to 1.65), and other efficacy outcomes. Lower RRs (in favor of teicoplanin) for clinical failure were observed with a lower risk of bias and when treatment was initiated for infections caused by gram-positive organisms rather than empirically. Total adverse events (RR, 0.61; 95% CI, 0.50 to 0.74), nephrotoxicity (RR, 0.44; 95% CI, 0.32 to 0.61), and red man syndrome were significantly less frequent with teicoplanin. Teicoplanin is not inferior to vancomycin with regard to efficacy and is associated with a lower adverse event rate than vancomycin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,401
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163 · cited 1×
“The effects of risk of bias assessment are reported as subgroup differences on the basis of a fixed-effect inverse variance meta-analysis (15).”
BackgroundRybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Epidemiology of Methicillin‐Resistant Staphylococcus aureus
Boucher, H. W., & Corey, G. R. (2008) · Clinical Infectious Diseases · doi:10.1086/533590 · Cited by 805
Soriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J. (2008) · Clinical Infectious Diseases · doi:10.1086/524667 · Cited by 767
Glycopeptide and Lipoglycopeptide Antibiotics
Kahne, D., Leimkuhler, C., Lu, W., & Walsh, C. (2005) · Chemical Reviews · doi:10.1021/cr030103a · Cited by 662
Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Lodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M., & Stellrecht, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-08 · Cited by 553
Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006
Sievert, D. M., Rudrik, J. T., Patel, J. B., McDonald, L. C., Wilkins, M. J., & Hageman, J. C. (2008) · Clinical Infectious Diseases · doi:10.1086/527392 · Cited by 483
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452
Steinkraus, G., White, R., & Friedrich, L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm258 · Cited by 420
Styers, D., Sheehan, D. J., Hogan, P., & Sahm, D. F. (2006) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-5-2 · Cited by 387
Walsh, T. R., Bolmström, A., Qwärnström, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P., & Diekema, D. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2439-2444.2001 · Cited by 319
Jauregui, L. E., Babazadeh, S., Seltzer, E., Goldberg, L., Krievins, D., Frederick, M., Krause, D., Satilovs, I., Endzinas, Z., Breaux, J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497271 · Cited by 312
Raad, I., Darouiche, R., Vazquez, J., Lentnek, A., Hachem, R., Hanna, H., Goldstein, B., Henkel, T., & Seltzer, E. (2005) · Clinical Infectious Diseases · doi:10.1086/427283 · Cited by 292
Stryjewski, M. E., Graham, D. R., Wilson, S. E., O’Riordan, W., Young, D., Lentnek, A., Ross, D. P., Fowler, V. G., Hopkins, A., Friedland, H. D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587896 · Cited by 289
Seltzer, E., Dorr, M. B., Goldstein, B. P., Perry, M., Dowell, J. A., Henkel, T., & Dalbavancin Skin and Soft-Tissue Infection Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/379015 · Cited by 231
Sivagnanam, S., & Deleu, D. (2003) · Critical Care · doi:10.1186/cc1871 · Cited by 230
Moise, P. A., Sakoulas, G., Forrest, A., & Schentag, J. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00939-06 · Cited by 225
Ansari, F. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg459 · Cited by 222
Nathwani, D., Morgan, M., Masterton, R. G., Dryden, M., Cookson, B. D., French, G., & Lewis, D. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn096 · Cited by 217
Staphylococcus aureus Community-Acquired Pneumonia During the 2006 to 2007 Influenza Season
Kallen, A. J., Brunkard, J., Moore, Z., Budge, P. J., Arnold, K. E., Fosheim, G. E., Finelli, L., Beekmann, S. E., Polgreen, P. M., Gorwitz, R. J., et al. (2008) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2008.04.027 · Cited by 177
Stryjewski, M. E., O'Riordan, W. D., Lau, W. K., Pien, F. D., Dunbar, L. M., Vallee, M., Fowler, V. G., Chu, V. H., Spencer, E., Barriere, S. L., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/429914 · Cited by 173
Stryjewski, M. E., Chu, V. H., O'Riordan, W. D., Warren, B. L., Dunbar, L. M., Young, D. M., Vallée, M., Fowler, V. G., Morganroth, J., Barriere, S. L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.862-867.2006 · Cited by 164
Fortún, J., Navas, E., Martínez‐Beltrán, J., Pérez‐Molina, J., Martín‐Dávila, P., Guerrero, A., & Moreno, S. (2001) · Clinical Infectious Diseases · doi:10.1086/320869 · Cited by 126
Glycopeptides: Update on an old successful antibiotic class
Pace, J., & Yang, G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.005 · Cited by 122
Gilbert, D. N., Wood, C. A., & Kimbrough, R. C. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.1.79 · Cited by 113
Decreased Teicoplanin Susceptibility of Methicillin-Resistant Strains of Staphylococcus aureus
Mainardi, J., Shlaes, D. M., Goering, R. V., Shlaes, J. H., Acar, J. F., & Goldstein, F. W. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1646 · Cited by 111
Robert, J., Bismuth, R., & Jarlier, V. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki486 · Cited by 98
Maor, ., Rahav, G., Belausov, N., Ben-David, D., Smollan, G., & Keller, N. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01262-06 · Cited by 84
Safety and efficacy of glycopeptide antibiotics
Finch, R. G., & Eliopoulos, G. M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki004 · Cited by 83
Brink, A. J., Richards, G. A., Cummins, R. R., & Lambson, J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.05.012 · Cited by 80
Menichetti, F., Martino, P., Bucaneve, G., Gentile, G., D’Antonio, D., Liso, V., Ricci, P., Nosari, A., Buelli, M., & Carotenuto, M. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2041 · Cited by 77
Kureishi, A., Jewesson, P. J., Rubinger, M., et al. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.11.2246 · Cited by 76
van der Auwera, P., Aoun, M., & Meunier, F. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.3.451 · Cited by 62
Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients
CHOW, A. W. C., Jewesson, P. J., Kureishi, A., et al. (1993) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1993.tb01901.x · Cited by 44
Laethem, Y. V., Hermans, P., Wit, S. D., Goosens, H., & Clumeck, N. (1988) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/21.suppl_a.81 · Cited by 41
Charbonneau, P., Harding, I., Garaud, J., Aubertin, J., Brunet, F. P., & Domart, Y. (1994) · Intensive Care Medicine · doi:10.1007/bf01713981 · Cited by 28
Cony‐Makhoul, P., Brossard, G., Pellegrin, G. M. J. L., et al. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb07934.x · Cited by 28
Liu, C., Lee, W., Fung, C.-P., Cheng, N.-C., Liu, C.-L., Yang, S.-P., & Chen, S.-L. (1996) · Clinical Drug Investigation · doi:10.2165/00044011-199612020-00003 · Cited by 24
Magilner, D., Byerly, M. M., & Cline, D. M. (2008) · North Carolina Medical Journal · doi:10.18043/ncm.69.5.351 · Cited by 18
Rolston, K. V., Bodey, G. P., & Chow, A. W. (1999) · Journal of Infection and Chemotherapy · doi:10.1007/s101560050037 · Cited by 9
Cited by
Methicillin-resistant Staphylococcus aureus
Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.33 · Cited by 1,556
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Gould, F. K., Denning, D. W., Elliott, T. S. J., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., & Watkin, R. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr450 · Cited by 593
Clinical management of Staphylococcus aureus bacteraemia
Thwaites, G. E., Edgeworth, J. D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Török, M. E., Walker, S., Wertheim, H. F., Wilson, P., & Llewelyn, M. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70285-1 · Cited by 261
Miyazu, D., Kodama, N., Yamashita, D., Tanaka, H., Inoue, S., Imakyure, O., Hirakawa, M., Shuto, H., & Kataoka, Y. (2016) · American Journal of Case Reports · doi:10.12659/ajcr.899149 · Cited by 27
“Teicoplanin is not inferior to vancomycin with regard to efficacy and is associated with fewer adverse events than vancomycin, including events requiring the discontinuation of treatment, nephrotoxicity, and red man syndrome [4].”
Background
Metadata
- Authors
- Svetitsky, S., Leibovici, L., & Paul, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-10
- Volume
- 53
- Issue
- 10
- Pages
- 4069-4079
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1995854195
- Cited by
- 275
- References
- 47
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.